Categories

Health Is Personal at the Connected Health Summit

“Because health is personal” is the tagline at the 2016 Connected Health Conference being held at the Gaylord Resort in National Harbor in metro Washington, DC. “Personal,” “Connected,” and “Health” are the three words that comprise the adjectives in the Personal Connected Health Alliance, the host of this conference. PCHA was formed through the merger of HIMSS, the health IT association, and Continua, the organization advocating for health technology “interoperability” — the ability for digital and communications technologies to communicate with each other, to remove friction from health data exchange. This week, PCHA announced that it will bring the Wireless-Life Sciences Alliance into

Comments(0)

Doctors who write right: Gawande, Topol and Wachter put people at the center of health/care

There’s a trifecta of books written by three brilliant doctors that, together, provide a roadmap for the 21st century continuum of health care: The Patient Will See You Now by Eric Topol, MD; The Digital Doctor from Robert Wachter, MD; and, Being Mortal, by Atul Gawande. Each book’s take provides a lens, through the eyes of a hands-on healthcare provider, on healthcare delivery today (the good, the warts and all) and solutions based on their unique points-of-view. This triple-review will move, purposefully, from the digitally, technology optimistic “Gutenberg moment” for democratizing medicine per Dr. Topol, to the end-game importance of

Comments(3)

What Mavis Staples taught us about health at SXSW

While I am all health, all-the-time when I’m at the annual South-by-Southwest meet-up in Austin, I had the opportunity to attend the premiere of the documentary, Mavis! (exclamation point included and appropriate, given the energy and joy in the title’s subject). “Mavis” is Mavis Staples, who you should know for her music, as singer with her family’s group, The Staple Singers; and, for as a positive force for good. In fact, she’s a lesson in whole health, which is why I’m writing about here on Health Populi which is dedicated to health where we live, work, play, pray…and sing. For

Comments(0)

Specialty pharmaceuticals’ costs in the health economic bulls-eye

This past weekend, 60 Minutes’ Leslie Stahl asked John Castellani, the president of PhRMA, the pharmaceutical industry’s advocacy (lobby) organization, why the cost of Gleevec, from Novartis, dramatically increased over the 13 years it’s been in the market, while other more expensive competitors have been launched in the period. (Here is the FDA’s announcement of the Gleevec approval from 2001). Mr. Castellani said he couldn’t respond to specific drug company’s pricing strategies, but in general, these products are “worth it.” Here is the entire transcript of the 60 Minutes’ piece. Today, Health Affairs, the policy journal, is hosting a discussion

Comments(1)

Big Data Come to Health Care…With Big Challenges – Health Affairs July 2014

“For Big Data, Big Questions Remain,” an article by Dawn Falk in the July 2014 issue of Health Affairs, captures the theme of the entire journal this month. That’s because, for every opportunity described in each expert’s view, there are also obstacles, challenges, and wild cards that impede the universal scaling of Big Data in the current U.S. healthcare and policy landscape. What is Big Data, anyway? It’s a moving target, Falk says: computing power is getting increasingly powerful (a la Moore’s Law), simpler and cheaper. At the same time, the amount of information applicable to health and health care

Comments(3)

Health care at an inflection point: digital trends via Mary Meeker

When Mary Meeker talks, the digerati listen. Meeker is the digital industry analyst who’s a partner at KPCB, a venture capital company, in Silicon Valley. Each year she publishes a report on the state of the digital marketplace. Her 2014 paper, Internet Trends 2014 – Code Conference (dated May 28 2014)  is online, and as usual, it’s full of data points on both digital technology segments along with some vertical industry findings – in education, financial services, and health, among other segments. I’ve combed through the 164 pages of the PDF to trend-weave the health implications. When it comes to health, the

Comments(1)

Pharma warming up to the cloud to drive efficiencies and support analytics

Over the next few years, large global pharma companies will need to wring out an additional $35 billion worth of efficiencies in order to drive profitability. While the industry has most of the patent cliff challenge behind it, companies face price constraints with respect to health reform, static national economies, and access demands. As the pharmaceutical industry enters the value-based health care era, the industry must catch up with other vertical markets in adopting information technology. In particular, pharma has been slower to migrate to the cloud than other businesses, with concerns about security and health care particular needs. Today, the

Comments(0)

23andme & Me

23andme received word from the Food & Drug Administration (FDA) on November 22, 2013, that they must cease and desist selling the company’s Saliva Collection Kit and Personal Genome Service (PGS). FDA explained in their Warning Letter, “Most of the intended uses for PGS listed on your website, a list that has grown over time, are medical device uses under section 201(h) of the FD&C Act. Most of these uses have not been classified and thus require premarket approval or de novo classification, as FDA has explained to you on numerous occasions. “Some of the uses for which PGS is intended are

Comments(5)

Delaying aging to bend the cost-curve: balancing individual life with societal costs

Can we age more slowly? And if so, what impact would senescence — delaying aging — have on health care costs on the U.S. economy? In addition to reclaiming $7.1 trillion over 50 years, we’d add an additional 2.2 years to life expectancy (with good quality of life). This is the calculation derived in Substantial Health And Economic Returns From Delayed Aging May Warrant A New Focus For Medical Research, published in the October 2013 issue of Health Affairs. The chart graphs changes in Medicare and Medicaid spending in 3 scenarios modeled in the study: when aging is delayed, more people qualify

Comments(0)

People not up-close-and-personal about personalized medicine…yet

Only 1 in 4 U.S. adults over 30 know what “personalized medicine” (PM) really is, and only 8% of people feel very knowledgeable about the concept based on Consumer Perspectives on Personalized Medicine from GfK, published online in August 2013. GfK surveyed 602 online adults 30 years and over between February and March 2013 drawn from the company’s KnowledgePanel sample of U.S. adults. Only 4% of people who have heard of personalized medicine describe it accurately as “medicine based on genome/genetic make up.” About one-half of people (52%) defined PM as medical care, treatment, or medicine geared toward individual needs. The poll

Comments(1)